Roche gets priority review from FDA for Hemlibra
ZURICH (Reuters) - Roche has been given fast-track review by the U.S. Food and Drug Administration (FDA) for its Hemlibra treatment for people with a form of haemophilia, the Swiss drugmaker said on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Food and Drug Administration (FDA) | Haemophilia | Health | Hemophilia | Switzerland Health